Cost-effectiveness  	Cost-effectiveness  	 NNP	B-NP
and  	and  	 CC	O
cost-utility  	cost-utility  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
of  	of  	 IN	I-NP
OTC  	OTC  	 NNP	I-NP
use  	use  	 NN	I-NP
of  	of  	 IN	I-NP
simvastatin  	simvastatin  	 CD	I-NP
10  	10  	 CD	O
mg  	mg  	 NN	B-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
primary  	primary  	 JJ	I-NP
prevention  	prevention  	 NN	I-NP
of  	of  	 IN	I-NP
myocardial  	myocardial  	 JJ	I-NP
infarction  	infarction  	 NN	I-NP
in  	in  	 IN	O
Iranian  	Iranian  	 JJ	O
men  	men  	 NNS	O
Several  	Several  	 JJ	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
and  	and  	 CC	O
meta-analyses  	meta-analyses  	 NNS	B-NP
have  	have  	 VBP	O
shown  	shown  	 VBN	O
the  	the  	 DT	O
advantageous  	advantageous  	 JJ	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
statins  	statins  	 NN	B-NP
in  	in  	 IN	O
populations  	populations  	 NNS	O
with  	with  	 IN	O
different  	different  	 JJ	O
levels  	levels  	 NNS	O
of  	of  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
disease  	disease  	 NN	I-NP
( 	( 	 -LRB-	O
CVD 	CVD 	 NNP	B-NP
)  	)  	 -RRB-	O
risk 	risk 	 NN	O
.  	.  	 .	O
Considering  	Considering  	 VBG	O
the  	the  	 DT	O
increasing  	increasing  	 VBG	O
cardiovascular  	cardiovascular  	 JJ	B-NP
risk  	risk  	 NN	I-NP
among  	among  	 IN	O
the  	the  	 DT	O
Iranian  	Iranian  	 JJ	O
population 	population 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
simvastatin  	simvastatin  	 CD	B-NP
10  	10  	 CD	O
mg 	mg 	 NN	B-NP
,  	,  	 ,	O
as  	as  	 IN	O
an  	an  	 DT	O
Over-The-Counter  	Over-The-Counter  	 JJ	B-NP
( 	( 	 -LRB-	O
OTC 	OTC 	 NNP	B-NP
)  	)  	 -RRB-	O
drug 	drug 	 NN	O
,  	,  	 ,	O
for  	for  	 IN	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
prevention  	prevention  	 NN	I-NP
of  	of  	 IN	I-NP
myocardial  	myocardial  	 JJ	I-NP
infarction  	infarction  	 NNS	I-NP
( 	( 	 -LRB-	O
MI 	MI 	 NNP	B-NP
)  	)  	 -RRB-	O
was  	was  	 VBD	O
evaluated  	evaluated  	 VBN	O
in  	in  	 IN	O
this  	this  	 DT	O
modeling  	modeling  	 JJ	O
study 	study 	 NN	O
,  	,  	 ,	O
from  	from  	 IN	O
the  	the  	 DT	O
payer 	payer 	 NN	O
's  	's  	 POS	O
perspective 	perspective 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
target  	target  	 NN	B-NP
population  	population  	 NN	I-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
hypothetical  	hypothetical  	 JJ	B-NP
cohort  	cohort  	 NN	I-NP
of  	of  	 IN	O
45-year  	45-year  	 NNP	O
CVD  	CVD  	 NNP	B-NP
healthy  	healthy  	 JJ	O
men  	men  	 NNS	O
with  	with  	 IN	O
an  	an  	 DT	O
average  	average  	 NN	O
( 	( 	 -LRB-	O
15 	15 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
10-year  	10-year  	 JJ	O
CVD  	CVD  	 NNP	B-NP
risk 	risk 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
semi-Markov  	semi-Markov  	 JJ	B-NP
model  	model  	 NN	I-NP
with  	with  	 IN	O
a  	a  	 DT	O
life-long  	life-long  	 JJ	B-NP
time  	time  	 NN	I-NP
horizon  	horizon  	 NN	I-NP
was  	was  	 VBD	O
developed  	developed  	 VBN	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
Cost-Utility-Analysis  	Cost-Utility-Analysis  	 JJ	B-NP
( 	( 	 -LRB-	O
CUA 	CUA 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
Cost-Effectiveness-Analysis  	Cost-Effectiveness-Analysis  	 NNP	B-NP
( 	( 	 -LRB-	O
CEA 	CEA 	 NNP	B-NP
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
OTC  	OTC  	 NNP	B-NP
simvastatin  	simvastatin  	 VBD	O
10  	10  	 CD	O
mg  	mg  	 NNS	B-NP
compared  	compared  	 VBN	O
to  	to  	 TO	O
no-drug  	no-drug  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
Two  	Two  	 CD	O
measures  	measures  	 NNS	O
of  	of  	 IN	O
benefits  	benefits  	 NNS	O
were  	were  	 VBD	O
used  	used  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
model 	model 	 NN	O
;  	;  	 :	O
Quality-Adjusted-Life-Years  	Quality-Adjusted-Life-Years  	 NNP	B-NP
( 	( 	 -LRB-	O
QALYs 	QALYs 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
the  	the  	 DT	O
CUA  	CUA  	 NNP	B-NP
and  	and  	 CC	O
Life-Years-Gained  	Life-Years-Gained  	 NNP	B-NP
( 	( 	 -LRB-	O
LYG 	LYG 	 NNP	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
the  	the  	 DT	O
CEA 	CEA 	 NNP	B-NP
.  	.  	 .	O
To  	To  	 TO	O
examine  	examine  	 VB	O
the  	the  	 DT	O
robustness  	robustness  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
results 	results 	 NNS	O
,  	,  	 ,	O
one-way  	one-way  	 JJ	B-NP
sensitivity  	sensitivity  	 NN	I-NP
analysis  	analysis  	 NN	I-NP
and  	and  	 CC	O
probabilistic  	probabilistic  	 JJ	B-NP
sensitivity  	sensitivity  	 NN	I-NP
analysis  	analysis  	 NN	I-NP
were  	were  	 VBD	O
applied  	applied  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
model 	model 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
the  	the  	 DT	O
base-case  	base-case  	 JJ	B-NP
scenario  	scenario  	 NN	I-NP
with  	with  	 IN	O
a  	a  	 DT	O
discount  	discount  	 NN	B-NP
rate  	rate  	 NN	I-NP
of  	of  	 IN	O
0 	0 	 CD	O
%  	%  	 NN	O
the  	the  	 DT	O
estimated  	estimated  	 JJ	O
ICERs  	ICERs  	 NN	B-NP
were  	were  	 VBD	O
1113  	1113  	 CD	O
USD 	USD 	 NNP	O
/ 	/ 	 NNP	O
QALY  	QALY  	 NNP	O
and  	and  	 CC	O
935USD 	935USD 	 FW	O
/ 	/ 	 FW	O
LYG  	LYG  	 FW	B-NP
per  	per  	 FW	O
patient  	patient  	 FW	O
( 	( 	 -LRB-	O
using  	using  	 VBG	O
governmental  	governmental  	 JJ	B-NP
tariffs 	tariffs 	 NNS	I-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
No  	No  	 DT	O
threshold  	threshold  	 NN	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
determined  	determined  	 VBN	O
in  	in  	 IN	O
Iran  	Iran  	 NNP	B-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
cost-effectiveness  	cost-effectiveness  	 JJ	I-NP
of  	of  	 IN	O
health-related  	health-related  	 JJ	O
interventions 	interventions 	 NNS	B-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
according  	according  	 VBG	O
to  	to  	 TO	O
the  	the  	 DT	O
recommendation  	recommendation  	 NN	B-NP
of  	of  	 IN	O
WHO 	WHO 	 WP	O
,  	,  	 ,	O
this  	this  	 DT	O
intervention  	intervention  	 NN	B-NP
can  	can  	 MD	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
highly  	highly  	 RB	O
cost-effective  	cost-effective  	 JJ	O
as  	as  	 IN	O
its  	its  	 PRP$	O
ICER  	ICER  	 NNP	B-NP
is  	is  	 VBZ	O
far  	far  	 RB	O
less  	less  	 JJR	O
than  	than  	 IN	O
the  	the  	 DT	O
reported  	reported  	 VBD	B-NP
GDP  	GDP  	 NNP	I-NP
per  	per  	 IN	O
capita  	capita  	 NN	B-NP
for  	for  	 IN	I-NP
Iran  	Iran  	 NNP	I-NP
by  	by  	 IN	O
World  	World  	 NNP	O
bank  	bank  	 NN	O
in  	in  	 IN	O
2013  	2013  	 CD	O
( 	( 	 -LRB-	O
$ 	$ 	 $	O
4763 	4763 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
This  	This  	 DT	O
modeling  	modeling  	 JJ	O
study  	study  	 NN	O
showed  	showed  	 VBD	O
that  	that  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
an  	an  	 DT	O
OTC  	OTC  	 NNP	B-NP
low  	low  	 JJ	O
dose  	dose  	 NN	B-NP
statin  	statin  	 NNS	I-NP
( 	( 	 -LRB-	O
simvastatin  	simvastatin  	 CD	B-NP
10  	10  	 CD	O
mg 	mg 	 CD	B-NP
)  	)  	 -RRB-	O
for  	for  	 IN	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
prevention  	prevention  	 NN	I-NP
of  	of  	 IN	I-NP
myocardial  	myocardial  	 JJ	I-NP
infarction  	infarction  	 NNS	I-NP
( 	( 	 -LRB-	O
MI 	MI 	 NNP	B-NP
)  	)  	 -RRB-	O
in  	in  	 IN	O
45-year  	45-year  	 CD	O
men  	men  	 NNS	O
with  	with  	 IN	O
a  	a  	 DT	O
10-year  	10-year  	 JJ	O
CVD  	CVD  	 NNP	B-NP
risk  	risk  	 NN	I-NP
of  	of  	 IN	O
15 	15 	 CD	O
%  	%  	 NN	O
could  	could  	 MD	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
highly  	highly  	 RB	O
cost-effective  	cost-effective  	 JJ	O
in  	in  	 IN	O
Iran 	Iran 	 NNP	B-NP
,  	,  	 ,	O
as  	as  	 IN	O
it  	it  	 PRP	O
meets  	meets  	 VBZ	O
the  	the  	 DT	O
WHO  	WHO  	 WP	B-NP
threshold  	threshold  	 VBD	O
of  	of  	 IN	O
the  	the  	 DT	O
annual  	annual  	 JJ	O
GDP  	GDP  	 NNP	B-NP
per  	per  	 FW	O
capita  	capita  	 FW	B-NP
( 	( 	 -LRB-	O
$ 	$ 	 $	O
4763 	4763 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
